The content on this site is intended for healthcare professionals only
Dr Matteo Lambertini speaks to ecancer about the present and future of precision oncology in breast cancer.
He begins by highlighting the current studies on PD-L1 expression in breast cancer; reviewing the IMpassion130 trial and the KEYNOTE-355 study design.
He continues by discussing genomic test’s clinical utility in HR+/HER2- early-stage breast cancer, touching on the RxPONDER trial.
Dr Lambertini continues his presentation by looking towards the future, suggesting more attention to germline testing beyond BRCA and exploiting the use of liquid biopsy treatment implications. Improvement of types of imaging techniques, specifically molecular imaging is also needed.
Adjuvant radiotherapy has no benefit following radical prostatectomy
Short-course radiation as effective as standard treatment for breast cancer patients choosing reconstruction after mastectomy
The 5-year long-term outcomes of radiation technique for locally advanced NSCLC
OncoAlert Round Up for August 25th - 31st, 2023
War in Ukraine: The Global Medical Knowledge Alliance's response to improving cancer care
Choosing Wisely in radiology Tanzania
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
The advantages of IORT for early breast cancer treatment
